At this time, there are no approved biosimilars for canakinumab, a human monoclonal antibody that inhibits interleukin-1 beta and is used to treat certain auto-inflammatory diseases. Therefore, no companies currently lead the canakinumab biosimilar market [1]. However, several companies have canakinumab biosimilars in various stages of development [1][2].

According to DrugPatentWatch.com, as of March 2023, there are at least 11 companies with canakinumab biosimilars in the pipeline [2]. These companies include, but are not limited to, Celltrion, Alteogen, and Torrent Pharmaceuticals [2].

It's important to note that the development and approval of biosimilars can be a lengthy and complex process, and there are many factors that can impact which biosimilars ultimately make it to market. As such, the landscape of the canakinumab biosimilar market is subject to change [1].

In summary, while there are no current leaders in the canakinumab biosimilar market, there are several companies with biosimilars in development. The specific companies and timing of market entry are subject to change.

Sources:

1. US Food and Drug Administration. (2021). Biosimilars. <https://www.fda.gov/drugs/biosimilars>
2. DrugPatentWatch.com. (2023). Canakinumab Biosimilars. <https://www.drugpatentwatch.com/drugs/canakinumab>